Lupus nephritis drug completes successful clinical trials
An experimental drug used to treat patients with lupus nephritis has successfully completed clinical trials and its maker will seek approval from the U.S. Food and Drug Administration in 2020. If approved, it would be the first drug approved to specifically treat lupus nephritis.
That’s great news for about a million people worldwide living with lupus nephritis, a chronic disease (and a form of lupus) in which a person’s own immune system attacks the kidneys, causing inflammation that progressively destroys kidney function. Because there are no drugs specifically for this disease, patients typically undergo treatment with a combination of immunosuppressive drugs and steroids.
In the Phase 3 clinical trial by Canadian manufacturer Aurinia Pharmaceuticals, the drug, called voclosporin, demonstrated a kidney response rate of 41% after one year compared to a response rate of 22.5% among control patients, a statistically significant improvement.
The company said in its announcement, “We are thrilled with the outcomes reported today from the AURORA trial, which unequivocally demonstrate the tremendous potential for voclosporin to play an important role in the treatment of the approximately one million people worldwide living with lupus nephritis.”
More information about lupus nephritis is available on AKF’s website.